HIV-2 INFECTION IN CZECHOSLOVAKIA

M. Brůčková, D. Kopecká, L. Syrůček, K. Vojtěchovský, V. Petkov

Institute of Hygiene and Epidemiology, Department of Epidemiology and Microbiology, 100 42 Prague, Czechoslovakia

Received July 11, 1988

Several cases of HIV-2 infection in Europe have been described recently, most of them in some relation to West Africa (1, 3, 5). In 1987 first two anti HIV-2 positive persons were identified in Prague, ČSSR. Both of them were male African students-one coming from Burkina Fasso, the other one from Mosambique. The HIV-2 antibody was detected in Pasteur Diagnostics commercial HIV-2 ELISA test and in Swedish "in house" ELISA HIV-2 test (2). The ELISA results were confirmed by Pasteur Diagnostics LAV-II and Swedish SBL 6669 Western blot assays. The Karpas HIV-2 immunoperoxidase test (4) kindly provided and performed in Prague laboratory by A. Karpas revealed also HIV-2 specific reaction in both serum specimens, Some cross reaction was observed in several ELISA HIV-1 commercial tests (DuPont, Electronucleonics, Organon) including weak reaction in Pasteur LAV-1 ELISA. Neither of these specimens reacted in Wellcome HIV-1 test which gave a negative proof for HIV-2 specific findings. Japanese HIV antibody test (Fujirebio) showed strongly positive results in both tested sera. It seems that many tests based on the use of whole virion HIV-1 antigen, detect in higher or lesser extent also HIV-2 antibody. This is not true for the Wellcome competitive test which is strictly HIV-1 specific. Some cross reactions were also noted in HIV-1 Western blots (Biorad, DuPont, Pasteur Diagnostics) especially in the gag protein region. This makes the diagnosis of HIV-2 infection even more difficult. The proper evaluation of laboratory results requires much experience. Apparently, we succeeded to prove the presence of HIV-2 antibodies in both African males studying in Prague. However, no HIV-2 antibody positive results were obtained so far in screening tests performed in several hundreds of sera from Czechoslovak population. Despite of this fact the potential risk of acquiring HIV-2 infection must be taken into account,

Acknowledgment. Authors are grateful Prof. Biberfeld, SBL, Stockholm and Prof. A. Karpas, Cambridge University Clinical School, for their kind help and for the supply of reagents.

References

- 1. Anonymous, P. N.: Nature (London), 332, 295, 1988.
- Biberfeld, G., Thorstensson, R., Bergström, M., Naucler, A., and Costa, C. M.: AIDS, 1988 (in press).
- 3. Brücker, G., Brun-Vézinet, F., Rosenheim, M., Rey, M. A., Katlama, G., and Gentilini, M.: Lancet, i, 223, 1987.
- Karpas, A., Hayhoe, G. F. J., Hill, F., Anderson, M., Tenant-Flower, M., Howard, L., and Oates, J. K.: Lancet, ii, 132, 1987.
- Marquart, K. H., Müller, H. A. G., and Brede, H. D.: AIDS, 2, 141, 1988.